NVO - Novo Nordisk stock jumps as experimental obesity drug shows promising early results
2024-03-07 07:06:17 ET
More on Novo Nordisk
- Novo Nordisk, A Very Healthy Pharma Stalwart
- Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
- Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
- Cigna in pact with Novo, Eli Lilly to widen obesity coverage
- Biden to push for expanding Medicare drug pricing program